Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27844200 | 0.87 | MAPT (0.53) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL29349693 | 0.86 | MAPT (0.72) | MAPTPOLBSMN1; SMN2RAB9AADRB1 | |
| SCHEMBL1392957 | 0.86 | MAPT (0.72) | MAPTPOLBSMN1; SMN2RAB9AADRB1 | |
| Ethoxycarbonyl Group SCHEMBL27908820 | 0.85 | MAPT (0.54) | MAPTPOLBSMN1; SMN2RAB9AADRB1 | |
| Hydrochloric Acid SCHEMBL30368622 | 0.85 | MAPT (0.70) | MAPTPOLBSMN1; SMN2RAB9AADRB1 | |
| Hydrochloric Acid SCHEMBL2683957 | 0.85 | MAPT (0.70) | MAPTPOLBSMN1; SMN2RAB9AADRB1 | |
| Tert-Butyl Formate SCHEMBL27960295 | 0.84 | MAPT (0.42) | MAPTPOLBSMN1; SMN2RAB9AADRB1 | |
| Tert-Butyl Formate SCHEMBL27714034 | 0.82 | SIRT6 (0.71) | MAPTPOLBSMN1; SMN2ADRB1SIRT6 | |
| SCHEMBL5659915 | 0.81 | MAPT (0.74) | MAPTPOLBSMN1; SMN2RAB9AADRB1 | |
| Tert-Butyl Formate SCHEMBL27722336 | 0.81 | CHRNB2 (0.47) | ADRB1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428731-A | Substituted 2-hydro-pyrazole derivatives as anti-cancer agents | 正大天晴药业集团股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-102186856-B | Pyrrolopyrimidines as CDK inhibitors | NOVARTIS AG | 2014-09-24 | — | — | CN | disclosed |
| CN-102369187-B | N- (hetero) aryl, 2- (hetero) aryl substituted acetamides as WNT signal modulators | IRM LLC | 2014-06-04 | — | — | CN | disclosed |
| CN-103788100-A | Pyrrolopyrimidine compounds as CDK inhibitors | NOVARTIS AG | 2014-05-14 | — | — | CN | disclosed |
| CN-103415516-A | Bicyclic inhibitors of ALK | ABBOTT LAB | 2013-11-27 | — | — | CN | disclosed |
| CN-102186856-A | Pyrrolopyrimidines as CDK inhibitors | NOVARTIS AG | 2011-09-14 | — | — | CN | disclosed |
| CN-101356159-A | Substituted isoquinoline-1, 3(2H,4H) -diones, 1-thio-1, 4-dihydro-2H-isoquinoline-3-ones and 1, 4-dihydro-3 (2H) -isoquinolones and their use as kinase inhibitors | WYETH CORP (US) | 2009-01-28 | — | — | CN | disclosed |
| CN-101163694-A | Imidaz0l0-5-yl-2-anil0-pyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB ASTRAZENECA UK (SE) | 2008-04-16 | — | — | CN | disclosed |